Analyst Price Target is $7.00
▲ +798.59% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Chemomab Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 798.59% upside from the last price of $0.78.
Current Consensus is
Moderate Buy
The current consensus among 3 contributing investment analysts is to moderate buy stock in Chemomab Therapeutics. This Moderate Buy consensus rating has held steady for over two years.